We evaluated the relationship between warfarin doses clinically determined according to INR and age, gender, body mass index, indication for the warfarin therapy, statins use, inherited thrombophilia and VKORC1, CYP2C9*C2 and CYP2C9*C3 gene polymorphisms. The gene discussed is CYP2C9; the disease is Rare hereditary thrombophilia.